The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score.
Zheng-Jun YangYu-Xiao LiuYue HuangZu-Jin ChenHao-Zhi ZhangYue YuXin WangXu-Chen CaoPublished in: Cancer medicine (2022)
subtype were more likely to have high RI for distance recurrence (RI-DR) and local recurrence (RI-LRR). Our newly defined classification has a better discrimination ability to predict survival outcome and recurrence score of Luminal B (HER2-negative) BC patients, which may help in clinical decision-making for individual treatment.